OMER may be a good short candidate. It needs 2 second phase III confirmatory trial. A market cap of $220M is overvalued.Its drug is just a reformulation of generic cheap components. Doctors are using them. Yes, they are useful, we know, but little pricing power.Press IGNORE button to analyst's hype.
One key issue: OMER need cash to run clinical trials. It has run out cash now.
And insiders are starting to sell by exercising cheap options. DEMOPULOS PETER A MD already filed report selling 11K shares.